Related Experiment Video
Updated: Jul 13, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
GDNF delivery for Parkinson's disease
Acta Neurochirurgica. Supplement
|August 19, 2007
Summary
Glial cell line-derived neurotrophic factor (GDNF) shows promise for Parkinson's disease (PD) treatment. Continuous intraputamenal infusion demonstrated sustained motor and daily living improvements in open-label studies.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Neurology
Background:
- Parkinson's disease (PD) treatments are primarily symptomatic and not neuroprotective.
- Neurotrophic factors, like glial cell line-derived neurotrophic factor (GDNF), offer potential neuroprotection and regeneration for dopaminergic neurons.
- Clinical administration of neurotrophic factors is challenging due to the blood-brain barrier.
Purpose of the Study:
- To evaluate the efficacy and safety of continuous intraputamenal glial cell line-derived neurotrophic factor (GDNF) infusion in Parkinson's disease (PD) patients.
- To assess the neuroprotective and neuroregenerative potential of GDNF in PD models and human trials.
- To investigate the clinical benefits and side effects of different GDNF administration methods.
Main Methods:
- Open-label studies involving continuous intraputamenal GDNF infusion in PD patients.
- Administration via viral vectors, intracerebroventricular (ICV) infusion, and direct intraputamenal infusion.
- Clinical assessments including UPDRS scores, dyskinesia evaluation, and positron emission tomography (PET) with 18F-dopa uptake.
- Autopsy analysis of brain tissue for tyrosine hydroxylase immunopositive nerve fibers.
Main Results:
- Continuous intraputamenal GDNF infusion showed excellent tolerance and few side effects in open-label studies.
- Patients experienced sustained motor and activities of daily living improvements (up to 63%) within 3 months, with sustained benefits up to 24 months.
- Significant increases in putamenal 18F-dopa uptake and tyrosine hydroxylase-positive nerve fibers were observed, indicating neuroprotection and regeneration.
- A subsequent randomized controlled trial did not meet predetermined clinical benefit levels, possibly due to technical differences.
Conclusions:
- Continuous intraputamenal GDNF infusion represents a promising neuroprotective and regenerative strategy for Parkinson's disease.
- GDNF delivery methods significantly impact clinical outcomes, with continuous infusion showing greater efficacy than bolus injections.
- Further research into optimal GDNF delivery is warranted to overcome challenges and maximize therapeutic potential in PD.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.